Single Dose Novel *Salmonella* Vaccine Enhances Resistance against Visceralizing *L. major* and *L. donovani* Infection in Susceptible BALB/c Mice

Juliane Schroeder¹, Najmeeyah Brown², Paul Kaye², Toni Aebischer¹,³

¹ Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, United Kingdom, ² Centre for Immunology and Infection, Hull York Medical School and Department of Biology, University of York, York, United Kingdom, ³ Robert Koch-Institute, Berlin, Germany

**Abstract**

Visceral leishmaniasis is a major neglected tropical disease, with an estimated 500,000 new cases and more than 50,000 deaths attributable to this disease every year. Drug therapy is available but costly and resistance against several drug classes has evolved. Despite all efforts, no commercial, let alone affordable, vaccine is available to date. Thus, the development of cost effective, needle-independent vaccines is a high priority. Here, we have continued efforts to develop live vaccine carriers based on recombinant *Salmonella*. We used an *in silico* approach to select novel *Leishmania* parasite antigens from proteomic data sets, with selection criteria based on protein abundance, conservation across *Leishmania* species and low homology to host species. Five chosen antigens were differentially expressed on the surface or in the cytosol of *Salmonella typhimurium* SL3261. A two-step procedure was developed to select optimal *Salmonella* vaccine strains for each antigen, based on bacterial fitness and antigen expression levels. We show that vaccine strains of *Salmonella* expressing the novel *Leishmania* antigens LinJ08.1190 and LinU23.0410 significantly reduced visceralisation of *L. major* and enhanced systemic resistance against *L. donovani* in susceptible BALB/c mice. The results show that *Salmonella* are valid vaccine carriers for inducing resistance against visceral leishmaniasis but that their use may not be suitable for all antigens.

**Citation:** Schroeder J, Brown N, Kaye P, Aebischer T (2011) Single Dose Novel *Salmonella* Vaccine Enhances Resistance against Visceralizing *L. major* and *L. donovani* Infection in Susceptible BALB/c Mice. PLoS Negl Trop Dis 5(12): e1406. doi:10.1371/journal.pntd.0001406

**Editor:** Diane McMahon-Pratt, Yale School of Public Health, United States of America

Received April 4, 2011; Accepted October 13, 2011; Published December 27, 2011

Copyright: © 2011 Schroeder et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a Marie Curie Grant EU-EXT-25435 to TA, and by MRC Programme Grant G0400786 to PMK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: AebischerT@rki.de

* Current address: Strathclyde Institute for Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, United Kingdom

**Introduction**

The leishmaniases are regarded as neglected tropical diseases. The causative protozoan parasites are transmitted through the bite of sandfly vectors. Currently an estimated 12 million people are infected, while 350 million people in 85 countries worldwide are at risk to develop one of the diseases associated with *Leishmania* parasites (http://www.who.int/leishmaniasis/burden/en/; [1]). The most severe form is visceral leishmaniasis (VL; also known as kala azar in India) a disease that is fatal if untreated. An estimated 500 000 new cases and 50 000 deaths are reported every year, with 90% occurring in Bangladesh, Nepal, India, Sudan, Ethiopia and Brazil ([2]). VL caused by *L. infantum*/*chagasi* is zoonotic with dogs being the main reservoir; however, in areas endemic for *L. donovani* (e.g. India and Sudan) the disease is anthropo-ontic.

In many cases infection remains asymptomatic, most likely indicating immune control. However, patients with symptomatic VL experience fever, fatigue, weight loss and weakness often accompanied by hepato-splenomegaly and anaemia and, if untreated, may die from bacterial co-infections, internal bleeding and anaemia (reviewed by [2]). Chemotherapy is available, but due to high toxicity, adverse side effects and emerging parasite resistance, treatment options are limited [3–6]. Long treatment regimens and associated costs are additional critical factors preventing patient access and compliance. For example paromomycin, a newly registered drug, is given by intra-muscular injections over a period of 21 days. Though the cheapest drug available, treatment still costs between 5 and 10 US$ per course, making this drug too expensive in relation to household income [5]. This economic burden of treatment is likely to remain for the foreseeable future. Thus, developing a vaccine for VL (and indeed for other forms of leishmaniasis) is high on the agenda of the World Health Assembly (resolution EB118.R3, Geneva 05/07).

Vaccination is considered possible because of the efficacy of the century-old practice of leishmanization against old world cutaneous leishmaniasis (CL), a treatment that affords life long protection as proven during its large scale use to protect military personnel in Israel, Iran and the former Soviet Union [7–9]. However, in some individuals, development of non-healing lesions, exacerbation of chronic disease and immunosuppression as a result of this procedure has been observed [10]. The unsatisfactory safety profile, its questionable efficacy against infection with heterologous species and logistic hurdles render leishmanization problematic. Vaccines that relied on autoclaved or merthiolate-killed whole promastigotes formulated with or without Bacillus Calmette-Guerin as adjuvants were developed to remedy some of the shortcomings of leishmanization but a recent meta-analysis of
Author Summary

The leishmaniases are tropical diseases that affect the poorest of the poor. They are caused by Leishmania species, protozoan parasites transmitted by blood sucking insects and the visceral form of the disease is fatal. Vaccines that would tremendously boost disease control strategies need to be designed cost-efficiently and for the existing infrastructure. Salmonella-based live vaccines could fulfil these requirements as they can be cheaply produced on an industrial scale and the lyophilized product can be stored at room temperature and upon rehydration is ready for oral, needle-free application. Salmonella, like Leishmania, are intracellular pathogens that primarily target host macrophages. The bacteria induce a viscerotropic immune response. Herein lies a potentially significant advantage of using attenuated Salmonella as delivery vehicles for parasite antigens for vaccination against visceral leishmaniasis. We used in vivo inducible promoters and optimized expression systems to construct attenuated Salmonella carriers that deliver novel vaccine antigens and show a host protective effect in small rodent models of visceral leishmaniasis. These proof-of-concept studies should serve to further promote exploration of live Salmonella as a cost effective and widely applicable carrier for vaccination against leishmaniases.

clinical studies evaluating these vaccines did not support their efficacy [11].

Clinical testing of vaccines based on recombinant Leishmania antigens or fractionated parasite material is much less advanced, although numerous antigenic proteins have been shown to have vaccine potential in pre-clinical models (see reviews by [12-14]).

Here, we adapted a reverse vaccinology [23] approach to define novel candidate vaccines, starting from proteomic data sets that were generated recently [24] and ignoring whether or not proteins would be recognized by sera from infected hosts. Moreover, we optimized recombinant attenuated Salmonella as a vaccine carrier platform since they had been explored before as vectors for anti-Leishmania vaccines [25-27] and have already been developed for vaccination purposes in humans [28-30].

Materials and Methods

Mice

Female BALB/c mice were purchased from Harlan UK, Charles River UK or bred and maintained under specific pathogen-free conditions in individually ventilated cages in the animal facilities of the School of Biological Sciences at the University of Edinburgh and the University of York. Animals were used at 6-9 weeks of age and were age matched within each experiment. All animal experiments adhered to the UK Animals (Scientific Procedures) Act 1986 and were conducted under Project Licenses granted by the UK Home Office and with local ethical approval (License # PPL 60/03581 to TA and PPL 60/ 03709 to PK).

Construction of expression plasmids

Inducibly express antigens on the surface of Salmonella, the E. coli adhesin involved in diffuse adherence (AIDA) autotransporter system was adapted and a variant of plasmid pKR143 [31] was constructed, pAIDA0, as previously described [32]. Briefly, the sequence encoding cholera toxin B subunit signal peptide was followed by SpeI/BglII sites for in-frame directional cloning of ORF of interest fused with downstream sequences coding for a hemagglutinin epitope (HA)-tag and the transporter domain of AIDA, all under the control of the in vivo inducible Mg2+-responsive PpagC promoter [33].

Vaccine antigen ORFs encoding L. donovani KMP-11 (LinJ35_V3.2260), ORF LinJ08.1190 (LinJ08_V3.1190), ORF LinJ09.1180 (LinJ09_V3.1180), ORF LinJ23.0410 (LinJ23_V3.0420), ORF LinJ25.1680 (LinJ25_V3.1670) and ORF LinJ 35.0240 (LinJ35_V3.0140) were amplified from L. donovani (MHOM/IN1/03BHU-55) genomic DNA using primers shown in table 1. ORF nomenclature and accession numbers are indicated in Table 2. Amplifications were carried out with the Platinum® Taq DNA Polymerase kit (Invitrogen). PCR products were digested with SpeI and BglII and cloned into the equally digested pAIDA0 for transformation into SL3261 and E. coli JK321 (UT5600 zdh::Tn10 dreh::kan) [34], respectively.

To differentially regulate protein expression levels, point mutations were introduced into the Shine-Dalgaro ribosomal binding sequence (RBS; underlined) using site directed mutagenesis. Forward primer for RBS3 (5’-GATCAATCTAGAATTAAAGACAGA- TATACATATGAAATAATTTGGTG-3’), RBS5 (5’-GATCAATCTAGAATTAAAGACAGA-TATACATATGAAATAATTTGGTG-3’), RBS6 (5’-GATCAATCTAGAATTAAAGACAGA-TATACATATGAAATAATTTGGTG-3’) were designed to amplify the cholera toxin signal peptide, HA-tag and antigen while simultaneously introducing the mutated Shine-Dalgaro sequence upstream of the signal peptide. The resulting PCR product was SpeI/BglII digested and re-ligated into pAIDA-Antigen. All resulting surface expression plasmids were subsequently named pVAC[# of RBS mutation]-antigen.

For expression of antigens in the salmonella cytosol L. donovani ORFs were amplified using primers described in Table 1. Resulting PCR products flanked by 5’tNde and 3’BamHI sites were digested and first cloned downstream of a PpagC promoter into a pBR322-derived plasmid series already containing mutated Shine-Dalgaro sequences (RBS1 – AGGAA, RBS2 – GGGAA and RBS3 – AGCGG) described in [35] for transformation into SL3261. The resulting plasmids were subsequently named pVAC[# of RBS mutation]-antigen. Preparation of live vaccine stocks, immunizations and determination of bacterial fitness by in vivo colonisation have been performed exactly as described before [32].
primers described above. Recombinant proteins were purified as described previously [32]. KMP-11, the only soluble protein was directly purified on a Nickel column (1 ml, HisTrap FF, GE Healthcare). All other antigens formed inclusion bodies which needed to be isolated and dissolved prior purification under denaturing conditions with an on-column refolding step [32].

Recombinant protein containing fractions eluted from columns (see Fig. S1) were pooled and protein concentrations determined using amidoblack [36]).

Table 1. List of primers used for amplifying antigens from parasite DNA.

| Antigen     | Expression system | Sequence 5′→3′ (enzyme restriction sites are shown in bold) |
|-------------|------------------|------------------------------------------------------------|
| KMP-11      | Surface psVAC    | F GATCAA ACTAGT GCCACCATGAGGAGAG                          |
|             | Cytosol pcVAC    | R GATCAAAGACCTTGTGATGGTACTGAGCAGCCC                      |
| LinJ08.1190 | Surface psVAC    | F GATCAA ACTAGT TCTCAGACGTCCTCC                           |
|             | Cytosol pcVAC    | R GATCAAAGACCTCGTGGACGTTCGGAGCAGCCC                      |
| LinJ09.1180 | Surface psVAC    | F GATCAA ACTAGT TCCCTCTGACAGGCGACTGG                    |
|             | Cytosol pcVAC    | R GATCAAAGACCTC AACTTTCCGGAGAACACAGT                      |
| LinJ23.0410 | Surface psVAC    | F GATCAA ACTAGT TCCCCTCTGACAGGCGACTGG                    |
|             | Cytosol pcVAC    | R GATCAAAGACCTCGTGGACGTTCGGAGCAGCCC                      |
| LinJ25.1680 | Surface psVAC    | F GATCAA ACTAGT TCTGCGAGGTCGATAGG                        |
|             | Cytosol pcVAC    | R GATCAAAGACCTC AACTTTCCGGAGAACACAGT                      |
| LinJ25.3680 | Surface psVAC    | F GATCAA ACTAGT TCTGCGAGGTCGATAGG                        |
|             | Cytosol pcVAC    | R GATCAAAGACCTC AACTTTCCGGAGAACACAGT                      |
| LinJ35.0240 | Surface psVAC    | F GATCAA ACTAGT TCTGCGAGGTCGATAGG                        |
|             | Cytosol pcVAC    | R GATCAAAGACCTC AACTTTCCGGAGAACACAGT                      |

Table 2. Nomenclature and accession numbers of genes encoding the novel antigens investigated.

| In manuscript | In TriTrypDB1) (version 22.06.2011) | NCBI Reference sequence Acc. Number |
|---------------|------------------------------------|-------------------------------------|
| LinJ08.1190   | LinJ08.1190                         | XM_001463411.1                      |
| LinJ09.1180   | LinJ09.1180                         | XM_001463538.1                      |
| LinJ23.0410   | LinJ23.0410                         | XM_001465681.1                      |
| LinJ25.1680   | LinJ25.1680                         | XM_001466162.1                      |
| LinJ35.0240   | LinJ35.0240                         | XM_001468797.1                      |

1) Aslett et al. TriTrypDB: a functional genomic resource for the Trypanosomatidae Nucleic Acids Research 2010 38(Database issue):D457–D462; doi:10.1093/nar/gkp851.
doi:10.1371/journal.pntd.0001406.t001

Live Anti-Leishmania Salmonella Vaccine

www.plosntds.org 3 December 2011 | Volume 5 | Issue 12 | e1406
Enzyme-linked immunosorbant assay

ELISA for antigen-specific antibodies of different isotypes (IgG1 and IgG2a) from mouse serum has been performed as previously described [32]. In brief, serial dilutions of individual sera were analysed. To estimate relative antibody concentrations, titers were determined corresponding to the value of the serum dilution giving a half maximal ELISA signal.

L. major infection and determination of parasite burden in limiting dilution assays

L. major promastigotes were grown in semi-defined medium until late stationary phase was reached. Two million parasites were injected into the left hind footpad and lesion size was measured as the difference in thickness between infected and uninfected footpad using a calliper. For determination of parasite numbers in organs mice were sacrificed by cerebral dislocation and organs (spleen, draining lymph node, footpad) were removed and homogenized. The single cell suspensions were adjusted to equal volumes and subjected to serial dilutions in 96-well tissue culture plates filled with SDM medium [24] supplemented with 20 μg/ml hygromycin and 50 μg/ml kanamycin, which was carried out in quadruplicates. After 14 days at 27°C, parasite growth was scored microscopically and parasite load in the infected organs was calculated using the dilution where at least 2 of 4 wells (≥37.5%) were positive [37]. This dilution was multiplied by the total volume (in multiples of 0.1 ml) to derive the total number of parasites per organ.

Determination of hepato-splenomegaly and L. donovani burden in impression smears

Mice were killed by cervical dislocation and livers and spleens were removed and weighed. The body-mass index (BMI) was calculated as the organ weight in percentage of body weight. To determine parasite burden in spleen and liver, impression smears were prepared on microscopic glass slides, fixed in methanol and stained with Giemsa. The number of parasites per 1000 host cell nuclei was counted using a light-field microscope and an immersion oil lens. Leishman-Donovan units (LDU) were calculated by multiplication of the number of parasites/1000 nuclei with the organ weight [38].

Histopathological analysis of hepatic response to L. donovani

Liver sections were processed for immunohistochemistry as described in detail elsewhere [39]. Briefly, confocal microscopy was performed on acetone fixed 8 μm frozen sections stained with Alexa 488-conjugated F4/80 (eBioscience, United Kingdom) and purified rabbit anti-mouse inducible nitric oxide synthase (iNOS) (Abcam, United Kingdom) detected with donkey anti-rabbit Alexa 647. Sections were counterstained with 4’,6-diamidino-2-phenylindole (DAPI), and mounted in Pro-Long Gold antifade (Invitrogen) for examination on a LSM META 510 confocal microscope (Zeiss). Quantification of NOS2 staining was performed on randomly selected fields for each mouse, using Adobe Photoshop CS3 to determine the area of iNOS reactivity (as number of positively stained pixels) relative to total granuloma area (as pixels stained with F4/80). Granuloma maturation was assessed from hematoxylin-eosin (H&E)-stained tissue sections as described elsewhere [39].

Statistical analysis

Statistical analysis was performed using GraphPad Prism Program (Version 4.0, GraphPad Software, San Diego, Califor-
plasmid cassettes each for cytosolic and surface antigen expression. These mutations resulted in staggered protein expression levels when *Salmonella* strains carrying the respective plasmids were grown under conditions that activate the PpagC promoter (Figure S2). Heterologous protein expression can greatly reduce fitness of the carrier bacteria in vivo, thereby critically affecting the amount of total antigen delivered to the immune system and thus vaccine immunogenicity. This relationship is schematically shown in Figure 2A (left panel) and, as an example, is shown for vaccine strains engineered for cytosolic expression of LinJ23.0410 (Figure 2A, right panel). Colonisation of the Peyer’s patches seven days after oral administration of 10^9 CFU was determined as a surrogate marker of protection against visceral leishmaniasis. Immunisation with the psVAC5-08.1190 and allstars vaccines significantly reduced parasitic numbers in the spleen compared to challenged only mice and a similar trend was noted for the surface expressing psVAC0-23.0410 vaccine (Figure 3D). Of note, five animals amongst those vaccinated with psVAC0-10.1190 and vaccine **Protection of mice against *L. major***

All selected strains were next tested in vivo for their ability to protect BALB/c mice against visceralising *L. major* infection. These mice are highly susceptible to *L. major* infection, and have been suggested to provide a good mouse model for VL. Mice were vaccinated with a single dose of *Salmonella* vaccine strains, the carrier control SL3261 or treated with PBS. Mice were subsequently challenged with 2×10^4 late-stationary phase *L. major* promastigotes into the left hind footpad. Lesion size was monitored over a course of several weeks after which mice were randomized and selected for analysis of parasitic burden in footpad, lymph node and spleen.

A pilot study involving all 10 selected vaccine strains showed that vaccination with *Salmonella* carrying antigens LinJ08.1190 and LinJ23.0410 reduced lesion size and parasitic burden compared to the controls (see Figure S3). Interestingly, vaccination with antigen LinJ25.1680 expressing *Salmonella* exacerbated disease while the other vaccines including the KMP-11-expressing strains had no effect on disease progression compared to controls (Figure S3).

Thus, differential results indicated that the KMP-11-expressing antigens were not optimal for the vaccine constructs. Hence, we decided to include the respective antigens from the initial pool. Protection of mice against *L. major* infection when analysing TNR-p55 receptor deficient mice [45] or when mapping susceptibility loci [46,47]. However, mechanisms are currently not fully understood. The discrepancy between lesion size and parasite burden was notable in mice vaccinated with psVAC0-23.0410, vaccine groups (Figure 3B, C) although a trend towards lower parasitic burdens was notable in mice vaccinated with psVAC0-23.0410, psVAC5-08.1190 and vaccine allstars, significantly delayed the onset and progression of footpad swelling in mice challenged nine weeks later (Figure 3A). Five weeks after infection, five animals per groups were selected randomly and parasitic burden in spleen, popliteal lymph node and footpad was determined. Parasite numbers in footpads and lymph nodes were not significantly different in the vaccine groups (Figure 3B, C) although a trend towards lower burdens was notable in mice vaccinated with psVAC0-23.0410, psVAC5-08.1190 and vaccine allstars (Figure 3B, C). The discrepancy between lesion size and parasite burden was surprising but is not without precedence. The inverse situation has been described in murine *L. major* infection when analysing TNR-p55 receptor deficient mice [45] or when mapping susceptibility loci [46,47]. However, mechanisms are currently not fully understood. The parasitic burden in the spleen was assessed as a surrogate marker of protection against visceral leishmaniasis. Immunisation with the psVAC5-08.1190 and allstars vaccines significantly reduced parasitic numbers in the spleen compared to challenged only mice and a similar trend was noted for the surface expressing psVAC0-23.0410 vaccine (Figure 3D). Of note, five animals amongst those vaccinated with psVAC0-08.1190 and vaccine...
allstars had no detectable parasites in the spleen (Figure 3D). Hence, a single oral dose of *Salmonella* vectored vaccines that delivered both LinJ08.1190 with LinJ23.0410 significantly reduced visceral *L. major* parasite burdens in these highly susceptible BALB/c mice.

Protection of mice against *L. donovani*

Since conservation of the antigens among *Leishmania* species was a key selection criterion, we hypothesised that antigens which were protective against *L. major* would also protect against the causative agent of human VL, *L. donovani*. To test this hypothesis, we immunised BALB/c mice with strains psVAC5-08.1190 and vaccine allstars. *Leishmania* surface antigen KMP-11 had been shown to be protective against *L. donovani* in mice [42]. Therefore and despite its poor performance in previous experiments, *Salmonella* strain pcVAC1-KMP, expressing KMP-11 in the cytosol, was included together with the carrier strain SL3261 and sham-immunisation in this study. Mice vaccinated with a single oral dose were challenged intravenously with $3 \times 10^7$ *L. donovani* amastigotes six weeks later. A characteristic for *L. donovani* infection in BALB/c mice is hepato-splenomegaly and the organ-specific control of the infection. Half of the mice were sacrificed on day 28 p.i., when liver parasite burden has usually reached its peak before the onset of self cure and when splenic parasite burden has begun to increase. The remaining animals were analysed at day 68 p.i. to assess long term control, particularly in the spleen.

An increased ratio of liver/spleen weight to body weight is an indirect measure of *L. donovani* infection induced inflammation and disease severity. Thus, body and organ weights were determined at necropsy (Table S1). The ratio for both liver (Figure 4A) and spleen (Figure 4B) increased between day 28 and day 68 in non-vaccinated animals and mice treated with either the carrier salmonella alone or the pcVAC1-KMP vaccine. In contrast, in animals vaccinated with psVAC5-08.1190 or the allstars vaccine,
this ratio either increased less dramatically or not at all (Figure 4A, B). Mice immunized with psVAC5-08.1190 or the allstars vaccine had a mean liver parasite burden of $84.20 \pm 39.30$ and $69.75 \pm 20.74$ LDU, respectively at day 68 p.i. significantly reduced in comparison to the non-immunized group ($361.0 \pm 66.79$ LDU), the SL3261 carrier ($189.0 \pm 63.79$ LDU) or the pcVAC1-KMP treated animals ($232.2 \pm 30.02$ LDU; Figure 4C). Of note, the decrease noted after SL3261 treatment in comparison with the naı¨ve controls was also significant (Figure 4C). The effects of the vaccines on splenic parasite burdens followed the same pattern (Figure 4D). Mice immunized with psVAC5-08.1190 or the allstars vaccine controlled parasite replication while numbers increased significantly between day 28 and 68 in all other study groups (Figure 4D). Immunisation with pcVAC1-KMP also did not protect mice from $L. donovani$ infection and parasite burden increased over time ($69.80 \pm 18.67$ to $182.8 \pm 61.53$), which was similar for SL3261 treated mice (Figure 4D).

In summary, a single oral dose of salmonella vectored vaccines delivering LinJ08.1190 and/or LinJ23.0410 significantly reduced hepato-splenomegaly and visceral infection in mice infected with $L. donovani$, the causative agent of human VL.

Immune responses

To assess immune responses during vaccination and infection, we measured antigen-specific antibody isotype titres as a surrogate of the underlying CD4+ T cell response, given the known correlation between IL-4 and IgG1 responses and between IFNγ and IgG2a [48]. Serum was assessed in vaccinated mice four weeks after immunisation and on day 28 and 68 post infection.
with *L. donovani* to test for antigen-specific antibodies. Four weeks after vaccination but before infection, vaccine antigen-specific antibody titers were below the limit of detection (Figure 5A–F). In agreement with the fact that KMP-11-specific antibodies are produced during human VL [49], infected non-vaccinated mice or SL3261 carrier immunized mice generated anti-KMP-11 antibodies (Figure 5A, B). This anti-KMP-11 response was very similar in the pcVAC1-KMP vaccinated group (Figure 5C). In contrast, vaccines expressing LinJ08.1190 and/or LinJ23.0410 primed animals for the production of specific antibodies that became detectable after the boosting infection on day 28 and 68 post infection (Figure 5D–F) but no antibodies against the respective recombinant proteins were detectable by ELISA (detection limit of assay was at titers ≤20) during infection in naïve, SL3261 or pcVAC1-KMP treated animals (not shown). This indicated that LinJ08.1190 and/or LinJ23.0410 were not naturally immunogenic during infection of BALB/c mice.

Next, the ratios of vaccine antigen-specific IgG1 and IgG2a were calculated for each mouse and time point (Figure 6) to seek evidence for a bias in type 1 vs. type 2 immune response. Over the course of infection significant and different skewing was noted between the treatment groups. Anti-KMP-11 IgG1 to IgG2a ratios were above 1 in pcVAC1-KMP vaccinated mice which was therefore not different from the response to KMP in infected only or SL3261 vaccinated mice. In comparison, anti-vaccine antigen specific IgG1 to IgG2a ratios, however, were significantly different in sera from psVAC5-08.1190 or allstars vaccinated mice with values around 1 or below (Figure 6; p≤0.05).

Figure 4. Vaccination significantly reduces *L. donovani* infection in BALB/c mice. Ten mice per group were immunised intra-gastrically with 1010 CFU salmonella vaccine strains and 6 weeks later infected with 3×10⁶ lesion-derived *L. donovani* amastigotes. Five mice per group were sacrificed at day 28 and five at 68 post infection. Animals were weighed and spleen and liver organ weights were determined to compute organ to body weight ratios for liver (A) and spleen (B). Giemsa stained impression smears of liver (C) and spleen (D) were assessed under the microscope and parasites per 1000 nuclei expressed as Leishman-Donovan Unit (LDU). * P≤0.05, ** P≤0.01, *** P≤0.001; one-way ANOVA and Tukey post-test. Error bars show standard error of the mean (SEM).

doi:10.1371/journal.pntd.0001406.g004

Live Anti-*Leishmania* Salmonella Vaccine

www.plosntds.org 8 December 2011 | Volume 5 | Issue 12 | e1406
Finally, to assess the underlying cellular response in a more direct manner, we examined the level of granulomatous inflammation in infected mice that were either unvaccinated or had been vaccinated with control SL3261 *Salmonella* or with allstars (Figure 7). At day 28 p.i., there was a small but significant increase in the number of granulomas observed in the liver of allstars vaccinated mice (Figure 7A). We next measured the maturation stage of each granuloma, using established scoring criteria [39]. Granuloma maturation was similar between all groups of mice at day 28 p.i. (with a small but not significant trend towards enhanced maturation in allstars vaccinated mice). By day 68 p.i., however, mice vaccinated with either SL3261 or allstars showed enhanced granuloma maturation compared to non-vaccinated mice. Although the results of this analysis are in keeping with the enhanced ability of these vaccinated mice to reduce parasite burden, it was not a sufficiently sensitive technique to discriminate between the resistance induced by SL3261 and allstars (c.f. Figure 4D). Finally, we measured the area within each granuloma that stained positive for iNOS, as one measure of functional capacity at these inflammatory foci. There were no significant differences in the iNOS response between vaccinated and non-vaccinated mice at either time point by this criterion (Figure 7D). Hence, the main tissue correlate of protection induced by allstars vaccination was an increase in the rapidity of granuloma formation, suggesting that vaccination may have heightened the frequency of CD4+ and/or CD8+ T cells able to facilitate this focal inflammatory response.

**Discussion**

We had previously reported on the proteome of the intracellular amastigote stage of *L. mexicana* [24] which showed extensive overlap with proteins identified in *L. donovani* axenic amastigotes [50]. Because of this overlap, the former proteomic dataset was exploited here to adapt a reverse vaccinology approach to develop a vaccine against VL. We applied the criteria of protein abundance, within parasite genus conservation, and absence of homologous proteins in host organisms to select novel candidate vaccine antigens aimed to induce cellular immunity. These criteria may not be optimal though to select targets for inducing antibody-dependent immunity. Four of five selected candidates could be

---

**Figure 5. Analysis of antigen-specific humoral response in vaccinated *L. donovani* infected mice.** IgG1 and IgG2a antibody isotypes specific for the respective vaccination antigen were determined in sera from each mouse individually by ELISA using plates coated with purified antigens KMP-11, LinJ08.1190 and LinJ23.0410. Titers of antibodies recognizing specific antigens of sera prepared at the indicated time points were shown from naive (A), SL3261 carrier control (B) and pcVAC1-KMP vaccine strain (C) immunized animals or psVAC5-08.1190 vaccine (D) or vaccine allstars (E, F) treated mice. Values represent mean titers calculated from individually tested sera. The test had a sensitivity to detect antibodies with titers of <20. Error bars show standard error of the mean (SEM). n.d. not detected. Statistical significance: * P<0.05, ** P<0.01 by two-tailed Mann-Whitney U test.

doi:10.1371/journal.pntd.0001406.g005

**Figure 6. Changes in IgG1 to IgG2a ratios in the course of *L. donovani* infection.** The ratios of antigen-specific IgG1 and IgG2a serum titres (as shown in Fig. 5) were calculated for sera of each individual mouse within their respective vaccination group for both time points (day 28 and day 68). Error bars show standard error of the mean (SEM).

doi:10.1371/journal.pntd.0001406.g006
expressed in recombinant form and when delivered by recombinant Salmonella two reduced and one exacerbated disease progression in a murine *L. major* infection model. These results suggest that the frequency of identifying immunologically relevant proteins by this method is high and may well be superior to previous strategies that relied on mRNA expression and genome data for antigen selection [51,52] with a hit frequency of 15%.

*Leishmania* like other kinetoplastids regulate gene expression mostly post-transcriptionally and mRNA abundance data alone may not be informative to predict protein abundance. However, as shown in other systems [40] and *Leishmania* [53] actual protein abundance in amastigotes is highly relevant if the protein is to become a target of the immune response [54]. Analysis of the proteome data sets suggested that bias in codon usage indicates translational bias and therefore is highly correlated with protein abundance [24]. Hence, codon usage may be used to rank ORFs and serve as a substitute parameter for protein abundance in the absence of real protein expression data to refine pure in silico selection of candidate antigens. This becomes particularly relevant for selecting membrane proteins that are severely underrepresented in current proteomic data sets.

The two protective antigens, LinJ08.1190 and LinJ23.0410, expressed by *Salmonella* carriers were immunogenic in these vaccines yet, based on antibody responses, were not a target of the immune response to *L. donovani* infection, at least not in mice. This is noteworthy since many *Leishmania* vaccine antigens including KMP-11 currently favoured by other groups have been identified using sera from patients [55–58]. Our findings with the salmonella vectored KMP-11 vaccine suggest that these immunoselection approaches may introduce an extra hurdle for vaccine development since the natural antigen-specific response may be skewed and, possibly, even be disease exacerbating [59,60]. The requirement for an additional type 1 immune response inducing adjuvants, IL-12, to achieve protective effects with a KMP-11 DNA vaccine in the murine *L. major* model [61] is in good agreement with this idea. Furthermore, a fusion protein called LEISH-F1 - also known as Leish-110F, Leish-111f or MML – was derived from the sequence of three immunoselected parasite antigens. LEISH-F1 is the most advanced protein-based subunit *Leishmania* vaccine in trial to date and has shown promising effects when tested in a therapeutic setting against human American CL [62]. However, this is not the case when used to prevent visceral canine disease after high dose experimental infection [63] or to treat naturally acquired VL in dogs [64]. In contrast, Leishmune®, a vaccine based on a glycoproteinic fraction of *L. donovani* that was not immunoselected, is licensed for the prevention of canine VL in Brazil and has shown efficacy in the field [65]. Interestingly, the Leishmune® vaccine antigens are poorly recognized by sera from dogs suffering from VL and vaccination therefore is not interfering with sero-surveillance programs [65]. Thus, reverse vaccinology based approaches as

**Figure 7. Hepatic granulomatous response in vaccinated mice.** Liver sections were taken from mice used to assess parasite burden (Fig. 4) and stained for iNOS and F4/80. Nuclei were counterstained with DAPI. (A). Number of granulomas per 50 random fields of view (*n* = 5 mice per time point). (B and C) Granuloma maturation status was graded as described in Materials and Methods into no response (hatched bar), immature (open bar), mature (grey bar) and empty (black bar). Data were obtained from ~50 granulomas per mouse and 4–5 mice at both day 28 (B) and day 68 (C) post infection. D: iNOS staining was assessed by determining the proportion of granuloma macrophage area that was stained for iNOS. Data are derived from between 35–90 granulomas from 5 mice per time point. doi:10.1371/journal.pntd.0001406.g007
presented here are likely to significantly broaden the choice of protective antigens.

A number of subunit vaccine delivery platforms, including purified proteins or mixtures of glycans and glycoproteins, recombinant DNA, viral and bacterial vectors have been evaluated experimentally in murine models of leishmaniasis (review by [12]. However, very few have entered or passed clinical testing and amongst them no vectored vaccine. We have chosen Salmonella as a carrier since these bacteria had already been positively evaluated by several groups in experimental models of leishmaniasis [25–27]. Moreover, they are being developed as recombinant carriers against a number of pathogens including Helicobacter pylori, Hepatitis B virus and Plasmodium falciparum [66,67]. In the context of a major neglected disease such as VL, their main advantages are their excellent safety profile, simple and low-cost production at industrial scale, possibility to store as lyophilized product at room temperature, and oral application route, thus reducing the requirements for extensive infrastructure. In addition, Salmonella are potent inducers of long-lived cell-mediated immunity including CD8+ T cells [28,68]. Induction of CD8+ T cells is particularly efficient by vaccines delivered by viral or bacterial carriers and may be a crucial characteristic of anti-Leishmania vaccines, since both CD4+ and CD8+ T cells are required for optimal anti-leishmanial immunity and granuloma formation [15–18]. While we do not yet have formal proof that our vaccines induced antigen-specific CD8+ T cells, bioinformatics analysis using CD8 T cell epitope/HLA-binding peptide prediction algorithms suggested epitopes presentable by major HLA alleles e.g. of human populations in VL endemic areas in India [69]. In the context of VL, Salmonella have the additional property to generate viscerotropic immune responses which may explain that the main protective effect was observed at the level of visceralizing infection in the L. major model. Moreover, depending on serovar, S. enterica exhibits broad or narrow host ranges. Serovar Typhimurium that was used here has the potential to deliver vaccine antigens in humans [70] as well as in dogs [71–73] while attenuated S. enterica Typhi can be engineered to deliver human vaccines [30,66].

In summary, we report the identification of two novel candidate vaccine antigens against VL by reverse vaccinology and the optimized construction of live Salmonella carriers. These VL vaccines could potentially be used to combat VL in the zoonotic, as well as the anthropogenic cycle of the disease.

Supporting Information

Figure S1 Post-column fractions of purified his-tagged antigens. His-tagged Leishmania antigens were expressed and purified from E. coli cell from inclusion bodies (LinJ23.0410 (A); LinJ08,1190 (B)) or lysates (KMP11 (C)) using nickel column liquid chromatography as described in Materials and Methods. Collected fractions were separated on SDS-Gels to determine yield and purity and selected fractions (box) were pooled and subsequently subjected to downstream processing such as dialysis and ultrafiltration.

Figure S2 Two-step strategy for the selection of vaccine strains expressing cytosolic KMP-11 for in vivo testing. Bacterial fitness (top panel) was determined as ability of the vaccine strain to colonize the Peyer’s patches of mice seven days after single dose oral administration of 10^10 CFU with KMP-11 expressing SL3261 (open symbols) or carrier SL3261 control (closed symbol; Schroeder and Aeberscher (32)). For antigen expression (bottom panel), bacterial strains were grown under conditions mimicking the intraphagosomal environment (low Mg2+, Ca2+) and thus activating F_{pagc} promoter activated vaccine antigen expression. Translational efficiency depended on ribosomal binding site sequences that were the only difference between expression plasmids pVAC0-3. 20 µg whole bacterial lysate per strain was loaded onto SDS gels and bands were visualized by coomassie stain. Black arrowhead indicates induced protein of interest (KMP-11).

Figure S3 Pilot-study to identify vaccine strains protective against L. major infection. Mice (10 per group) were immunised orally with a single dose of 10^10 CFU of Salmonella vaccine strains carrying the indicated vaccine antigen expression plasmids or the carrier control SL3261. Twelve weeks later animals were challenged with 2 x 10^5 L. major promastigotes into the left hind foot pad. Lesion size (A) was monitored with a calliper using the uninfected right foot as reference. Values represent mean swelling in mm and bars show standard errors of the mean (SEM). Asterisks denote statistical thresholds * P<0.05, ** P<0.01, *** P<0.001 determined by two-tailed Mann-Whitney U test. Seven weeks after infection, three mice per group were randomly selected for determination of parasite burden in the foot pad (B), draining lymph node (D and spleen (C) were by limiting dilution assay as described in Materials and Methods. n.d. denotes not determined.

Table S1 Organ and body weights were determined for each mouse in the respective groups immunized with SL3261 or SL3261 carrying the indicated vaccine antigen expression plasmid in comparison to a group of untreated mice. Five mice per group per time point were killed by cervical dislocation and livers and spleens were removed and weighed. The body-mass indices (BMIs; see Fig. 4 in main manuscript) were calculated based on the mean weight values. n.d. = not done.

Acknowledgments

We would like to thank Asher Maroof for technical advice and discussion.

Author Contributions

Conceived and designed the experiments: JS TA PK. Performed the experiments: JS NB TA. Analyzed the data: JS NB TA PK. Contributed reagents/materials/analysis tools: JS TA NB PK. Wrote the paper: JS PK TA.

References

1. Herwaldth BL (1999) Leishmaniasis. Lancet 354: 1191–1199.
2. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873–882.
3. Polonio T, Efferth T (2008) Leishmaniasis: drug resistance and natural products. Int J Mol Med 22: 277–286.
4. Lira R, Sundar S, Makharia A, Kenney R, Gan A, et al. (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antivirus-resistant strains of Leishmania donovani. J Infect Dis 180: 564–567.
5. Melcheux F, Balasesquem M, Olliaro P, Sundar S, Rijal S, et al. (2010) Cost-Effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis 4(8): e00818.
6. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, et al. (2005) Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis 5: 763–774.

www.plosntds.org
7. Nadim A, Javadian E, Tahvildar-Bidgani G, Ghorbani M (1983) Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filières 76: 377–383.

8. Khamaisipour A, Rafati S, Davoudi N, Mahboudi F, Modabber F (2006) Leishmania vaccine-candidate development: a global overview. Indian J Med Res 123: 423–438.

9. Khamaisipour A, Dowlati Y, Asilian A, Hashemi-Fesharaki R, Javadi A, et al. (2005) Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23: 3642–3648.

10. Hosseini SM, Hattam GR, Arshaki S (2005) Characterization of Leishmania isolated from unhealed lesions caused by leishmanization. East Mediterr Health J 11: 240–243.

11. Noazin S, Khamaisipour A, Moulton LH, Tanner M, Nasserii K, et al. (2009) Efficacy of killed-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 27: 4747–4753.

12. Kedzierski L. (2010) Leishmaniasis Vaccine: Where are We Today? J Glob Infect Dis 2: 177–185.

13. Okwor I, Uzonna J (2009) Vaccines and vaccination strategies against human cutaneous leishmaniasis. Hum Vaccin 5: 291–301.

14. Costa CHN, Peters NC, Maruyama SR, de Brito EC, Jr., de Miranda Santos IKF, et al. (2011) Vaccines for the Leishmaniasis: Proposals for a Research Agenda. PLoS Negl Trop Dis 5: e945.

15. Stager S, Alexander J, Karb AC, Boto M, Rooijen NV, et al. (2003) Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 9: 1287–1292.

16. Baru R, Bhaumik S, Haldar AK, Naskar K, De T, et al. (2007) Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect Immun 75: 5956–5966.

17. Müller I, Kropf P, Etges RJ, Louis JA (1993) Gamma interferon response in Salmonella enterica serovar Typhimurium primary-booster vaccination biases towards T helper 1-like responses. Infect Immun 61: 3730–3738.

18. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, et al. (1997) Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania. J Exp Med 186: 1137–1147.

19. Dumontel E. (2009) Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Infect Genet Evol 9: 1075–1082.

20. Palnik-de-Sousa CB (2008) Vaccines for leishmaniasis in the forthcoming 25 years. Curr Opin Immunol 20: 709–724.

21. Coler RN, Reed SG (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244–249.

22. Stober CB, Lange UG, Roberts MT, Gillimart B, Francis R, et al. (2009) From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 24: 3602–3615.

23. Rappaoli R (2000) Reverse vaccination. Curr Opin Microbiol 3: 445–450.

24. Paape D, Lipponer C, Schmid M, Ackermann B, Barrios-Llerena ME, et al. (2000) Transgenic, fluorescent Leishmania mexicana allow direct analysis of the antigenic profile of intracellular amastigotes. Mol Cell Proteomics 7: 1680–1701.

25. Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, et al. (1990) Antigenic expression of the major leishmanial glycoprotein 63 with different promoters. Infect Immun 65: 171–178.

26. McSorley SJ, Xu D, Liew FY (1997) Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. Infect Immun 65: 171–178.

27. Lange UG, Mastroeni P, Blackwell JM, Stober CB (2004) DNA-based immunization with Ty21a-based Salmonella vaccines. Gut 57: 1065–1072.

28. Salerno-Goncalves R, Wyant TL, Pasetti MF, Fernandez-Vina M, Tacket CO, et al. (2008) Transgenic, fluorescent Leishmania donovani delivers cytokines and infection: role of CD8+ T cells. Infect Immun 86: 3730–3738.

29. Bhanukumar S, Basu R, Bhaumik K, De T, et al. (2005) Kinetoplastid membrane-protein-11 DNA vaccination induces complete protection against both pentavalent antimony-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activation and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174: 7160–7171.

30. Rollestonen C, Sorensen M, Rizos K, Hovritz B, Bumann D (2004) Antigen selection based on expression levels during infection facilitates vaccine development for an intracellular pathogen. Proc Natl Acad Sci U S A 101: 8739–8744.

31. Hsu J, Genschel J, Miko D, Weidz L, Eidel C, et al. (1999) Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci U S A 96: 1430–1436.

32. Kinality ST, Nashlaneas M, Hordzweiz B, Scott P (1999) TNF receptor p55 is required for elimination of inflammatory mononuclear cells following control of intracellular pathogens. J Immunol 163: 3833–3839.

33. Sandhiankeswesare A, Elso CM, Simpson K, Curis JM, Kumar B, et al. (2005) The wound repair response controls outcome to cutaneous leishmaniasis. Proc Natl Acad Sci U S A 102: 15551–15556.

34. Handman E, Elso C, Foote S (2003) Genes and susceptibility to leishmaniasis. Adv Parasitol 53: 71–1.75.

35. Snapper CM, Paul WE. (1987) Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236: 944–947.

36. Trujillo C, Raincover R, Veloz ID, Restchi C (1999) The humoral immune response to the kinetoplastid membrane protein-11 in patients with American leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes. Immunol Lett 70: 205–209.

37. Rodelo Leishmaniasis metabolism: from sand fly gut to human macrophage. FASEB J 22: 590–602.

38. Stober CB (2004) From genomes to vaccines for leishmaniasis. Methods Mol Biol 227: 423–439.

39. Almeida R, Norishi A, Levick M, Verdis D, Freeman T, et al. (2002) From genomes to vaccines: Leishmania as a model. Philos Trans R Soc Lond B Biol Sci 357: 3–11.

40. Aebischer T, Wolfram M, Patzer SL, Ilg T, Wiese M, et al. (2000) Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect Immun 68: 1328–1336.

41. Patterh, P, Aebischer T (1999) Antigen presentation by macrophages harboring intravesicular pathogens. Parasitol Today 15: 325–332.

42. Forberg M, Bauli R, Roychouchoury K, Thierent S, Roy S, et al. (2006) Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS One 1: e60.

43. Forberg M, Grillich S, Sharav T, Sterry W, Walden P (2009) Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous leishmaniasis. PLoS One 4: e8376.

44. Sralky VA, Guelerian JA, Benson DR, Baelzor O, Carvalho EM, et al. (1995) A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 181: 1527–1537.

45. Goto Y, Coler RN, Guderian J, Mohamath R, Reed SG (2006) Cloning, characterization, and serodiagnostic evaluation of Leishmania membrane protein-11 DNA vaccination induces complete protection against lethal muramidase-sensitive and -resistant strains of Leishmania donovani, but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 27: 1306–1316.
62. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, et al. (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28: 6581–6587.

63. Moreno J, Nieto J, Masina S, Canavate C, Cruz I, et al. (2007) Immunization with H1, HASP61 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 25: 5290–5300.

64. Miret J, Nascimento E, Sampaio W, Franca JC, Fujinawa RT, et al. (2008) Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f+MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 26: 1585–1594.

65. Palatnik-de-Sousa CB, Silva-Antunes I, Morgado AA, Menz I, Palatnik M, et al. (2009) Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas. Vaccine 27: 3505–3512.

66. Galen JE, Pasetti MF, Tennant S, Ruiz-Olvera P, Sztein MB, et al. (2009) Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol 87: 400–412.

67. Aebischer T, Walduck A, Schroeder J, Wehrens A, Chijioke O, et al. (2008) A vaccine against Helicobacter pylori: towards understanding the mechanism of protection. Int J Med Microbiol 298: 161–168.

68. Salerno-Gonzalves R, Sztein MB (2009) Priming of Salmonella enterica serovar Typhi-specific CD8+ T cells by suicide dendritic cell cross-presentation in humans. PLoS One 4: e5079.

69. Schroeder J, Aebischer T (2011) Vaccines for Leishmaniasis: From proteome to vaccine candidates. Hum Vaccin 7: 10–15.

70. Angelakopoulos H, Hohmann EL (2008) Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 68: 2135–2141.

71. Petavy AF, Hormaeche C, Lahmar S, Ouhelli H, Chabalgoity A, et al. (2008) An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study. PLoS Negl Trop Dis 2: e125.

72. McVey DS, Changappa MM, Mosier DE, Stone GG, Oberst RD, et al. (2002) Immunogenicity of chiH127 phoP- Salmonella enterica serovar Typhimurium in dogs. Vaccine 20: 1618–1623.

73. Chabalgoity JA, Moreno M, Carol H, Dougan G, Hormaeche CE (2000) Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine. Vaccine 19: 460–469.